

1 **Title:** Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits
2 in Zambia: a repeated cross-sectional survey, 2021-2022

3
4 *Authors:* Elizabeth Heilmann^{1,2}, Tannia Tembo³, Sombo Fwoloshi⁴, Bupe Kabamba⁵, Felix Chilambe⁶,
5 Kalubi Kalenga³, Mpanji Siwingwa⁶, Conceptor Mulube⁵, Victoria Seffren⁷, Carolyn Bolton-Moore³, John
6 Simwanza², Samuel Yingst², Ruchi Yadav⁷, Eric Rogier⁷, Andrew F. Auld², Simon Agolory⁷, Muzala Kapina⁸,
7 Julie R. Gutman⁷, Theodora Savory³, Chabu Kangale⁵, Lloyd B. Mulenga⁴, Izukanji Sikazwe^{3,†}, Jonas Z.
8 Hines^{2,*,†}

9
10 *Affiliations:*

- 11 1. Public Health Institute, Oakland, CA, USA
- 12 2. U.S. Centers for Disease Control and Prevention, Lusaka, Zambia
- 13 3. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
- 14 4. Ministry of Health, Lusaka, Zambia
- 15 5. PATH, Lusaka, Zambia
- 16 6. University Teaching Hospital, Lusaka, Zambia
- 17 7. U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
- 18 8. Zambia National Public Health Institute, Lusaka, Zambia

19
20 * Corresponding author

21 † These authors contributed equally to this report

22

23 *Corresponding author:*

24 Jonas Hines

25 Email: jhines1@cdc.gov

26 Address: Centers for Disease Control and Prevention, 351 Independence Ave, Lusaka, Zambia

27

28 *Keywords:* COVID-19/epidemiology; COVID-19 Serological Testing; SARS-CoV-2; Seroepidemiologic

29 Studies; Public Health Surveillance; Epidemiology/trends; Pregnant Women; Zambia; Africa

30

31 **Abstract**

32 *Background* SARS-CoV-2 serosurveys help estimate the extent of transmission and guide allocation of
33 COVID-19 vaccines. We measured SARS-CoV-2 seroprevalence among women attending ANC clinics to
34 assess exposure trends over time in Zambia.

35 *Methods* We conducted repeated cross-sectional surveys among pregnant women aged 15-49 years
36 attending their first ANC visits in four districts of Zambia (two urban and two rural) during September
37 2021-September 2022. Serologic testing was done using a multiplex bead assay which detects IgG
38 antibodies to the nucleocapsid protein and the spike protein receptor-binding domain (RBD). We
39 calculated monthly SARS-CoV-2 seroprevalence by district. We also categorized seropositive results as
40 infection alone, infection and vaccination, or vaccination alone based on COVID-19 vaccination status
41 and anti-RBD and anti-nucleocapsid test results.

42 *Findings* Among 8,304 participants, 5,296 (63.8%) were cumulatively seropositive for SARS-CoV-2
43 antibodies. SARS-CoV-2 seroprevalence primarily increased from September 2021 to September 2022 in
44 three districts (Lusaka: 61.8-100.0%, Chongwe: 39.6-94.7%, Chipata: 56.5-95.0%), but in Chadiza,
45 seroprevalence increased from 27.8% in September 2021 to 77.2% in April 2022 before gradually
46 dropping to 56.6% in July 2022. Among 5,906 participants with a valid COVID-19 vaccination status,
47 infection alone accounted for antibody responses in 77.7% (4,590) of participants.

48 *Interpretation* Most women attending ANC had evidence of prior SARS-CoV-2 infection and most SARS-
49 CoV-2 seropositivity was infection-induced. Capturing COVID-19 vaccination status and using a multiplex
50 bead assay with anti-nucleocapsid and anti-RBD targets facilitated distinguishing infection-induced
51 versus vaccine-induced antibody responses during a period of increasing COVID-19 vaccine coverage in
52 Zambia. Declining seroprevalence in Chadiza may indicate waning antibodies and a need for booster

53 vaccines. ANC clinics have a potential role in ongoing SARS-CoV-2 serosurveillance and can continue to

54 provide insights into SARS-CoV-2 antibody dynamics to inform near real-time public health responses.

55

56 Introduction

57 SARS-CoV-2 was first detected in Zambia on March 18, 2020.¹ Since then, the Zambia National Public
58 Health Institute (ZNPPI) has reported nearly 350,000 COVID-19 cases over four main epidemic waves.²
59 Confirmed case counts underreport the true extent of SARS-CoV-2 infections due to the high proportion
60 of subclinical infections, limited testing supplies, and surveillance gaps. SARS-CoV-2 seroprevalence
61 studies can help bridge the gap in understanding SARS-CoV-2 transmission. In Zambia, a survey of six
62 districts found a pooled prevalence of 10.6% in July 2020 and estimated that 92 infections occurred for
63 every reported case.³ Another study conducted in a peri-urban district in February 2021 measured a
64 seroprevalence of 33.7%.⁴ No studies have been published measuring SARS-CoV-2 seroprevalence in
65 Zambia following the Delta and Omicron waves.

66 Repeated cross-sectional surveys leveraging existing healthcare platforms can help monitor trends in
67 seroprevalence during ongoing transmission while minimizing implementation costs associated with
68 large-scale household surveys. Antenatal care (ANC) clinics have been utilized in several countries in
69 Africa to monitor SARS-CoV-2 seroprevalence in a healthy population of women accessing healthcare
70 services.⁵⁻⁹ In Ethiopia, SARS-CoV-2 surveillance conducted in ANC clinics between April 2020 and March
71 2021 first detected SARS-CoV-2 antibodies in June 2020 and peaked at 11.8% in February 2021.¹⁰
72 Repeated cross-sectional serosurveys in ANC clinics in Kenya found that most women were seropositive
73 for SARS-CoV-2 antibodies by October 2021.¹¹

74 Early SARS-CoV-2 serosurveys measured antibodies to estimate total infections, but COVID-19 vaccine
75 rollout now clouds seroprevalence interpretations. Detectable antibodies may be the result of SARS-
76 CoV-2 infection, COVID-19 vaccination, or both. Serologic assays with nucleocapsid and spike targets in
77 combination with COVID-19 vaccination history can distinguish these groups in countries, like Zambia,
78 where most vaccines administered target the spike protein.¹² COVID-19 vaccines first became publicly

79 available in Zambia in April 2021.¹³ After a slow rollout initially, the Ministry of Health announced
80 achieving 70% coverage of the targeted population on November 1, 2022.¹⁴ Most COVID-19 vaccine
81 doses received and distributed in Zambia have been the spike-targeting Janssen (61%) and Pfizer-
82 BioNTech (20%) vaccines.¹³

83 In Zambia, 97% of women attend at least one ANC visit during pregnancy, and antenatal attendees have
84 long served as a sentinel population for HIV, syphilis, and malaria surveillance.¹⁵⁻¹⁷ Whether this platform
85 can be leveraged to monitor COVID-19 remains unknown. We aimed to estimate monthly
86 seroprevalence of SARS-CoV-2 antibodies among pregnant women attending first antenatal care visits at
87 selected health facilities in four districts of Zambia from September 2021 to September 2022.

88

89 **Methods**

90 *Study setting and population*

91 We conducted repeated cross-sectional surveys of women attending first ANC visits in four districts
92 (Chadiza, Chipata, Chongwe, and Lusaka) of Zambia from September 2021 to September 2022. Data
93 collection began after Zambia's third epidemic wave caused by the Delta variant (May-August 2021) and
94 encompassed the fourth COVID-19 wave driven by the Omicron variant (December 2021-March 2022).

95 The four districts were purposefully selected to capture a range of urban (Chipata and Lusaka) and rural
96 (Chadiza and Chongwe) communities and districts with points-of-entry into Zambia (e.g., international
97 airport in Lusaka and land borders with Malawi and Mozambique in Chipata and Chadiza, respectively).

98 A sample size of 200 women per district per month was selected based on available resources and an
99 acceptable margin of error for the expected range of SARS-CoV-2 seroprevalence estimates over the
100 study period. Ten facilities per district were randomly selected using probability proportional to the

101 average number of ANC enrollments per month among health facilities reporting an average of at least
102 19 antenatal enrollments per month in 2020. Each facility in Chipata, Chongwe, and Lusaka districts
103 enrolled up to 20 participants per month among pregnant women aged 15-49 years attending their first
104 ANC visits. A health worker provided information on the study during group counseling sessions when
105 the health facility provided routine first-time ANC services. Pregnant women willing to participate were
106 screened for eligibility and, if consenting, were enrolled in the study until 20 participants were recruited
107 per facility each month. In Chadiza District, all women attending the first ANC were approached for
108 participation as part of a larger malaria surveillance pilot project, and up to 200 samples were selected
109 post-enrollment for SARS-CoV-2 serologic testing per month.¹⁸ (For months with >200 participants in
110 Chadiza, within each month, records were ordered by facility and interview date and the first 20
111 participants' specimens were tested for SARS-CoV-2. If a facility had fewer than 20 participants in a
112 month, specimens from other sites in Chadiza were selected and tested based on interview date until
113 the sample size of 200 was reached.) SARS-CoV-2 surveillance in Chadiza goes until July 2022 (instead of
114 September 2022) when the malaria surveillance project ended. At all sites, women were screened for
115 acute COVID-19 prior to enrollment, and those exhibiting symptoms were referred for COVID-19 testing
116 and case management per government protocols and excluded from the study.

117 *Data collection and sample processing*

118 Participants were administered an electronic questionnaire on tablets using the Open Data Kit platform
119 (Get ODK Inc., San Diego, CA, USA) to gather demographic data, SARS-CoV-2 exposures, COVID-19
120 vaccination, and routine ANC test results (i.e., HIV, syphilis, hepatitis, and malaria). Possible SARS-CoV-2
121 exposures included participants or households prior positive SARS-CoV-2 test and sustained close
122 contact with a suspected or known COVID-19 case. COVID-19 vaccination and prior COVID-19 statuses
123 were self-reported. Study staff attempted to verify COVID-19 vaccination information from vaccination
124 cards if participants had them available on the day of their ANC visit. From February 2022 onward,

125 participants self-reported inter-district and international travel, frequency of visits to churches, funerals
126 or weddings, markets, and indoor dining, and use of public transportation and face masks to provide a
127 general sense of COVID-19 risk behaviors.

128 Whole blood was collected on filter paper as dried blood spots (DBS) using the same finger prick or
129 venipuncture from routine ANC testing. HIV, syphilis, hepatitis B, and malaria tests were conducted
130 according to national guidelines, subject to the availability of test kits. Chipata, Chongwe, and Lusaka
131 district specimens were transported to a central laboratory for testing at University Teaching Hospital
132 (Lusaka, Zambia) and Chadiza District specimens were transported to PATH laboratory (Lusaka, Zambia)
133 for testing. Serologic testing was done using the FlexImmArray SARS-CoV-2 Human IgG Antibody Test
134 (Tetracore Inc, Rockville, MD, USA) on the MAGPIX platform (Luminex Corp, Austin, TX, USA) according
135 to manufacturer instructions with DBS preparation as described by Tartof et al.¹⁹⁻²⁰ The assay was
136 verified in-country in conjunction with the US CDC prior to its use. This multiplex bead assay has three
137 SARS-CoV-2 targets: nucleocapsid (N) protein, the receptor binding domain (RBD) of the spike-1 protein,
138 and a N-RBD fusion protein. Signal ratios were calculated for each target as the median fluorescent
139 intensity of the protein divided by the average calibrator median fluorescent intensity from each plate.
140 Samples with signal ratios ≥ 1.2 for all three targets were considered SARS-CoV-2 IgG positive with past
141 SARS-CoV-2 exposure, and samples with a signal ratio ≤ 0.9 for any target were considered SARS-CoV-2
142 IgG negative. Signal ratios > 0.9 and < 1.2 were considered indeterminate and the samples were re-run.
143 Valid results of the second test were retained in the final dataset. Samples with indeterminate results
144 after re-testing were categorized as SARS-CoV-2 IgG negative. Samples with persistent quality control
145 issues were removed from the final dataset.

146 *Statistical analysis*

147 SARS-CoV-2 seroprevalence was estimated as the number of positive cases divided by the total number
148 of tests with valid results by month and district. Seroprevalence was adjusted based on the assay
149 sensitivity (89.8%) and specificity (100.0%) from an independent test.²¹ Trend analysis was conducted to
150 compare SARS-CoV-2 seroprevalence with district-level COVID-19 case reports provided by ZNPHI.²
151 District-level populations exposed to SARS-CoV-2 were calculated using 2022 Census population
152 projection estimates from the Zambia Statistics Agency and peak SARS-CoV-2 seroprevalence estimates
153 during data collection.²² These peak estimates of persons exposed to SARS-CoV-2 were compared to the
154 total number of reported COVID-19 cases at the end of the study to estimate the ratio of reported cases
155 to total SARS-CoV-2 infections in each district.

156 In a sub-analysis, target-specific assay results and COVID-19 vaccination status were analyzed to group
157 antibody responses into no evident response (anti-RBD negative), infection only (anti-RBD positive,
158 unvaccinated), vaccination only (anti-RBD positive, vaccinated, anti-N negative), or vaccination and
159 infection (anti-RBD positive, vaccinated, anti-N positive) based off the decision tree developed by Duarte
160 et al.¹² Antibody responses in participants who received an unknown or inactivated virus vaccine were
161 classified as indeterminate. Wilcoxon rank sum tests were used to compare signal ratios for each assay
162 target by antibody response category. Logistic regression controlling for enrollment month was used to
163 identify factors associated with seropositivity and calculate adjusted odds ratios. Sub-analyses were
164 conducted among participants who reported prior confirmed COVID-19 and those who had received a
165 COVID-19 vaccine. Analyses were conducted using R version 4.2.1 (R Foundation for Statistical
166 Computing, Vienna, Austria).

167

168 **Results**

169 Between September 2021 and September 2022, 9,221 pregnant women attending their first ANC visits
170 were enrolled. A total of 8,558 (92.8%) samples were tested; among those, 8,304 (97.0%) valid SARS-
171 CoV-2 antibody results were matched to participant questionnaires (Chadiza: 1,616, Chipata: 2,099,
172 Chongwe: 2,441, Lusaka: 2,148). Two-hundred and fifty four specimens could not be linked to
173 questionnaire data, so were not included in the analysis.

174 The median age of participants was 25 years (interquartile range [IQR]: 20-30; supplementary table 1).
175 The majority (57.9%) of participants achieved primary education or less and most were unemployed
176 (40.2%) or farmers (24.9%). Only 2.2% of women reported having COVID-19 prior to study enrollment,
177 3.3% reported confirmed COVID-19 in the household, and 3.9% reported close contact with a confirmed
178 or suspected COVID-19 case outside the household. About half of participants responded that they wore
179 a mask all or most of the time in public (49.5%) or were observed to be wearing a face mask properly
180 during the ANC visit (49.3%). Vaccination coverage of one or more COVID-19 vaccine doses increased
181 from 4.4% in September 2021 to 26.6% in September 2022. Most vaccinated women (1,274/1,688) had
182 received the Janssen vaccine and 87.4% were considered fully vaccinated with the primary series.
183 Routine ANC testing for syphilis and hepatitis B was reported in less than half of participants (40.2% and
184 11.7%, respectively), but most (96.7%) women were tested for HIV or knew their HIV status prior to the
185 visit and 8.8% were positive.

186 Overall, 5,296 (63.8%) participants were SARS-CoV-2 seropositive. Seroprevalence was highest in Lusaka
187 and lowest in Chadiza throughout the study period (figure 1). In Lusaka, SARS-CoV-2 adjusted
188 seroprevalence rose from 61.8% (95% confidence interval [CI]: 52.8-70.5%) in September 2021 to
189 100.0% in August and September 2022 (August 95% CI: 97.2-100.0; September 95% CI: 100.0-100.0).

190 SARS-CoV-2 seroprevalence also peaked near 100% in August 2022 in Chipata (97.3% [91.7-100.0]) and
191 Chongwe (96.8% [91.9-100.0]) districts but dropped slightly in September 2022 (95.1% [89.0-99.7] and
192 94.7% [89.6-98.8], respectively). In Chadiza, SARS-CoV-2 seroprevalence peaked at 77.2% (95% CI: 61.8-
193 78.6) in April 2022 and then gradually dropped to 56.6% (95% CI: 46.7-66.5) when data collection ended
194 in July 2022. The greatest single month increase in urban districts (Lusaka and Chipata) was from
195 December 2021 to January 2022 during the peak of the Omicron wave in Zambia, while in rural districts
196 (Chadiza and Chongwe), the greatest increases were seen in March and April 2022, respectively.

197 In the sub-analysis exploring target-specific assay results and COVID-19 vaccination status, 6,042 (72.8%)
198 were positive for anti-RBD IgG and 6,343 (76.4%) were positive for anti-N IgG. Overall, 2,053 (24.7%)
199 participants had no detectable antibodies to the RBD or nucleocapsid proteins, and 345 (4.2%) were
200 indeterminate (supplementary figure 1). Among 5,906 participants with anti-RBD antibodies and a valid
201 COVID-19 vaccination status, most (77.7%) were likely infection-induced only, 20.6% from vaccination
202 and infection, and only 1.6% vaccination-induced alone. Infection-induced antibodies were the most
203 common throughout the study period while hybrid infection and vaccination antibody responses
204 became more common over time (figure 2). In Chadiza, hybrid antibodies surpassed infection-induced
205 starting in April 2022. In comparing target-specific signal ratios by antibody response category, no
206 difference was observed for the nucleocapsid target (figure 3). For the RBD target, the median signal
207 ratio was significantly higher among participants who were vaccinated and infected compared to
208 participants who were infected or vaccinated alone, and the median signal ratio for participants who
209 were only infected was greater than for those who were only vaccinated.

210 Pairwise logistic regression adjusting for enrollment month identified different factors associated with
211 SARS-CoV-2 serostatus in each district (table 1). Women aged 40-49 years in Chipata had nearly three
212 times the odds of seropositivity compared to women aged 15-19 years (aOR: 2.76 [95% CI: 1.16-6.58]),
213 but age was not significantly associated with serostatus elsewhere. In Chadiza and Chongwe districts,

214 women who had completed secondary education or higher had greater odds of SARS-CoV-2
215 seropositivity compared to women with some primary education (Chadiza aOR: 1.76 [1.17-2.64];
216 Chongwe aOR: 1.64 [1.16-2.31]). Significant differences were observed in SARS-CoV-2 seroprevalence by
217 occupation in all districts except Chadiza. In Chipata, women living with HIV (WLHIV) had higher odds of
218 seropositivity compared to HIV-negative women (aOR: 1.42 [1.05-1.90]), although this association was
219 no longer significant after further adjusting for age group (aOR: 1.29 [0.95-1.76]).

220 SARS-CoV-2 seropositivity was significantly associated with prior confirmed COVID-19 only in Chadiza
221 (aOR=3.06 [1.55-6.07]; table 1). Among 179 reported prior COVID-19 cases, 130 (72.6%) were SARS-CoV-
222 2 seropositive at the time of enrollment. The median time between COVID-19 diagnosis and first ANC
223 visit was 9 months (IQR: 7-14) among women who tested SARS-CoV-2 seropositive and 8 months (IQR:
224 4-13) among seronegative women ($p = 0.13$).

225 COVID-19 vaccination was associated with significantly higher odds of SARS-CoV-2 seropositivity in all
226 four districts, adjusting for enrollment month (table 1). Among vaccinated women, SARS-CoV-2
227 serostatus did not differ by partial vs. full primary vaccine series or vaccine type (table 2). Compared to
228 women who received their first COVID-19 vaccine dose within one month prior to study enrollment,
229 participants who received their first dose one to five months prior had greater odds of testing SARS-CoV-
230 2 seropositive, controlling for enrollment month and district (aOR: 1.58 [1.19-2.10]).

231 Twenty-one percent of the 179 participants with prior COVID-19 reported being hospitalized.
232 Hospitalization and time between COVID-19 and enrollment were not associated with SARS-CoV-2
233 serostatus, but COVID-19 vaccination was associated with greater odds of seropositivity among these
234 women (OR: 4.32 [2.07-9.02]; table 3).

235 District-level cumulative incidence was calculated from 2022 population projections and reported
236 COVID-19 cases from March 2020 through the end of the survey (July 2022 for Chadiza and September

237 2022 elsewhere) and ranged from 1.1% in Chadiza District to 3.5% in Lusaka District (table 4). Overall,
238 90,150 COVID-19 cases were reported in the four districts from March 2020 to September 2022 but we
239 estimated that 2,911,393 people had evidence of SARS-CoV-2 exposure. The ratio of SARS-CoV-2
240 seroprevalence to cumulative incidence was 29:1 in Lusaka District, 31:1 in Chadiza District, 39:1 in
241 Chipata District, and 92:1 in Chongwe District.

242

243 **Discussion**

244 SARS-CoV-2 seroprevalence was high among participants and nearly all first ANC attendees in three out
245 of four study districts had evidence of SARS-CoV-2 infection. In those districts, seroprevalence generally
246 increased over the 13-month study period, while in Chadiza, it declined from April to July 2022. Lower
247 seroprevalence in Chadiza District was expected, being the most rural of the study districts. The very
248 high seroprevalence in Lusaka District was also expected given a study conducted at two Lusaka
249 hospitals which found that 36.9% of women attending ANC clinics between March and July 2021 (part of
250 the Delta wave, prior to this study) were positive for SARS-CoV-2 by RT-PCR.²³ The large rise in SARS-
251 CoV-2 seroprevalence from November 2021 to March 2022 when the Omicron wave occurred was
252 similar to what was seen in South Africa where seroprevalence among the general population was 73%
253 before the Omicron wave and 91% after.²⁴⁻²⁵ This high seroprevalence was proposed as a reason for the
254 lack of significant transmission waves after Omicron, despite the emergence of Omicron sub-lineages
255 with greater infectivity and low COVID-19 vaccine coverage.²⁵

256 COVID-19 vaccination among participants was low and most SARS-CoV-2 antibodies were likely
257 infection-induced. COVID-19 vaccination was associated with higher odds of SARS-CoV-2 seropositivity
258 and COVID-19 vaccination in combination with SARS-CoV-2 infection produced the strongest immune
259 response, both of which could be explained by a robust immune response caused by hybrid immunity.²⁶

260 Other studies in Africa also measured higher SARS-CoV-2 seroprevalence among vaccinated participants,
261 higher neutralizing antibody titers among participants with infection and vaccination, and faster waning
262 of antibodies post-vaccination among participants who had not been infected.^{7,27-29} These results
263 support the recommendation for COVID-19 vaccination (including booster doses) regardless of past
264 infection. COVID-19 vaccination campaigns were conducted throughout Zambia during the study period,
265 but vaccine coverage among study participants was lower than the general population, possibly
266 reflecting hesitancy toward vaccination during pregnancy, and only about 12% of the fully vaccinated
267 population has received a booster dose.² COVID-19 messages and risk mitigation strategies addressing
268 the concerns of pregnant women can be incorporated seamlessly into routine ANC to prevent adverse
269 outcomes in this population at higher risk for severe COVID-19. Healthcare providers can screen for
270 symptoms of COVID-19, malaria, and tuberculosis simultaneously, and COVID-19 vaccines may be
271 administered alongside tetanus boosters.

272 The ratios of SARS-CoV-2 seroprevalence to cumulative incidence were lower than the 1:92 ratio
273 previously measured in a July 2020 serosurvey in other parts of Zambia.³ This reduction mirrors the
274 downward global trend in seroprevalence to cumulative incidence ratios since 2020 (i.e., improving case
275 detection ratios) and may be due to evolving testing strategies and increased availability and use of
276 rapid antigen test kits.³⁰ Interpretation of these ratios late in the pandemic is complicated by
277 reinfections, waning antibodies, and non-report of home RDT results, leading to an underestimation of
278 total SARS-CoV-2 infections. Some past SARS-CoV-2 infections may not be detectable as antibodies wane
279 over time and people with asymptomatic infections or mild clinical cases may mount less of an immune
280 response.³¹ This is consistent with the women who were SARS-CoV-2 seronegative despite reporting
281 prior COVID-19 and may explain the declining seroprevalence observed in some districts and months.

282 Older age, higher education, and urban versus rural location were all associated with higher
283 seroprevalence during the July 2020 survey in Zambia, and similar associations were noted in some

284 districts during this study.³ This may reflect differences in access to COVID-19 information and infection
285 prevention supplies or in the ability to comply with COVID-19 risk mitigation guidelines among certain
286 subpopulations. These factors may intersect with occupation which was also associated with differences
287 in seroprevalence in most districts. Diverse work environments, such as open fields for farming, compact
288 cubicles in an office, or crowded market stalls, could impact an individual's SARS-CoV-2 exposure risk.
289 Similar associations were noted in Mozambique where market sellers and those engaged in formal
290 employment had higher SARS-CoV-2 seroprevalence than other community members.²⁹ Furthermore,
291 modes of transportation might vary by urban/rural status, which could in turn affect risk of coming into
292 contact with SARS-CoV-2. Tailored COVID-19 prevention messaging for demographic groups with higher
293 SARS-CoV-2 seroprevalence may help reduce transmission during future waves. These observed
294 differences in SARS-CoV-2 prevalence by certain demographic groups could simply reflect differences in
295 COVID-19 risk for different groups in the population.

296 Most COVID-19 mitigation strategies in Zambia were carried out nationally by the Ministry of Health.
297 Given the differences in SARS-CoV-2 risk factors and seroprevalence trends by district, subnational
298 strategies may be more suitable in the future to mitigate COVID-19 risk where and when needed.
299 District or provincial level responses could help direct resources to areas of high transmission while
300 avoiding imposing strict measures in areas with low transmission where the social and economic
301 burdens of mitigation efforts may outweigh the benefit of reducing transmission. This approach was
302 used to lift masking requirements in Zambia as districts reached 70% vaccination coverage and
303 demonstrates that robust surveillance systems and quality tracking of key COVID-19 indicators at the
304 district level can facilitate subnational decision-making.³²

305 This study has several limitations. First, we could not estimate a single population-weighted
306 seroprevalence because of the non-systematic selection of districts and participants. Our study was
307 limited to women aged 15-49 years and may not be representative of populations that may be more or

308 less susceptible to SARS-CoV-2 infection. However, a global meta-regression analysis found no
309 difference in seroprevalence by sampling frame comparing studies among pregnant women to
310 household and community surveys.³⁰ As with all SARS-CoV-2 seroprevalence surveys, our estimates
311 depend on serologic test performance. The manufacturer's requirement of testing positive for all three
312 targets for an overall positive sample is more conservative than single target assays and may have
313 excluded some past infections. Waning of SARS-CoV-2 antibodies might have resulted in
314 underestimation of seroprevalence, and variability in the waning time for different antibody types could
315 have biased the sub-analysis findings categorizing infection/vaccination statuses. Studies have shown
316 that anti-nucleocapsid antibodies wane more quickly than anti-spike antibodies,³³⁻³⁴ although anti-N
317 antibody prevalence was slightly greater than anti-RBD antibody prevalence in our study. Adjusting the
318 seroprevalence estimates based on a test sensitivity of 90% likely helped but the potential for
319 misclassification remains. Given the cross-sectional study design, we could not assess whether those
320 who were seronegative had truly never been exposed to SARS-CoV-2, had been exposed and never
321 mounted a detectable antibody response, or had sero-reverted before testing. Lastly, we were uncertain
322 how the premature ending of SARS-CoV-2 surveillance in Chadiza in July 2022 affected the overall
323 seroprevalence estimates for this study.

324 Despite these limitations, our study also has notable strengths. We measured SARS-CoV-2
325 seroprevalence over 13 months which encompassed periods before, during, and after Zambia's Omicron
326 wave. The study period also spanned early COVID-19 vaccine rollout in Zambia, and the use of a
327 multiplex bead assay with spike and nucleocapsid targets allowed us to distinguish seropositivity from
328 infection versus vaccination. We included several districts which had not been included in previous
329 SARS-CoV-2 seroprevalence studies and found substantial geographic variation, particularly in the most
330 rural study district. Finally, we demonstrated the feasibility of integrating SARS-CoV-2 serosurveillance
331 into routine health services which may be adaptable to future epidemics.

332 As the COVID-19 pandemic continues to evolve, so does the role of seroprevalence studies. While our
333 study shows that most people living in Zambia have likely been exposed to SARS-CoV-2, seroprevalence
334 studies may still play a valuable role in understanding waning population immunity over time and
335 susceptibility to emerging variants. Longitudinal cohort studies may be better suited than cross-sectional
336 surveys to meet these needs, and ANC may continue to be a useful platform for recruiting participants
337 as women attend frequent follow-up visits during pregnancy and postpartum periods.

338

339 *Author Contributions:* EH, TT, SF, BK, CBM, SY, JRG, VS, LM, IS, and JZH designed the study. TT, BK, and
340 KK monitored data and sample collection, transport, and storage. FC, MS, and CM performed the lab
341 analysis, and VS, RY, and ER interpreted the lab results. EH, JS, MK, and JZH accessed and verified the
342 underlying data. EH analyzed the data and produced the figures. EH wrote the first draft of the
343 manuscript and all other coauthors reviewed and approved of the final version. All authors had access to
344 the study data and approved the final copy of the manuscript for publication submission.

345 *Ethics statement:* This study was authorized by the National Health Research Authority (NHRA) through
346 an expedited review of COVID-19 related studies. For Chadiza District, the SARS-CoV-2 data collection
347 and serologic testing were reviewed and approved by the University of Zambia Biomedical Research
348 Ethics Committee as an amendment to a pre-existing malaria surveillance protocol. This activity was
349 reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See e.g., 45
350 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42U.S.C. §241(d); 5 U.S.C. §552a;44 U.S.C. §3501 et seq). All
351 methods were carried out in accordance with relevant guidelines and regulations. Written informed
352 consent was obtained for all participants before enrollment. Pregnant women under 18 years are
353 considered emancipated minors in Zambia for the purpose of providing their own informed consent.

354 *Funding statement:* This research was financially supported by the Centers for Disease Control and
355 Prevention (CDC) Emergency Response to the COVID-19 pandemic and the President's Emergency Plan
356 for AIDS Relief (PEPFAR) through the CDC under the terms of cooperative agreements with the Centre
357 for Infectious Disease Research in Zambia (5 NU2GGH002251-02-00) and the Public Health Institute (5
358 NU2GGH002093-05-00). No additional external funding was received for this study. The funders had no
359 role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

360 *Data Availability Statement:* The data that support the findings of this study are available from Zambia
361 Ministry of Health, but restrictions apply to the availability of these data, which were used under license

362 for the current study, and so are not publicly available. Data are however available from the authors
363 upon reasonable request and with permission of Zambia Ministry of Health. Interested researchers
364 should submit a research proposal to the CDC Zambia science office at: zm-ads@cdc.gov. If approved,
365 the requestor must sign a data use agreement. Additionally, the study protocol is available for request.

366 *Competing interests:* The authors have read the journal's policy and have the following competing
367 interests: There are no patents, products in development, or marketed products associated with this
368 research to declare. The authors have declared that no competing interests exist.

369 *Authorship Disclaimer:* The findings and conclusions in this report are those of the author(s) and do not
370 necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

371

372 References


- 373 1. Chipimo PJ, Barradas DT, Kayeyi N, et al. First 100 Persons with COVID-19 – Zambia, March 18–April
374 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69(42)**: 1547–48.
- 375 2. Zambia National Public Health Institute. Zambia COVID-19 Dashboard. Mar 14, 2023.
376 <https://www.arcgis.com/apps/dashboards/3b3a01c1d8444932ba075fb44b119b63> (accessed Apr
377 13, 2023).
- 378 3. Mulenga LB, Hines JH, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July,
379 2020: a cross-sectional cluster sample survey. *Lancet Glob Health* 2021; **9**: e773–81.
- 380 4. Shanaube K, Schaap A, Klinkenberg E, et al. SARS-CoV-2 seroprevalence and associated risk factors in
381 periurban Zambia: a population-based study. *Int J Infect Dis* 2022; **118**: 256–63.
- 382 5. National Institute for Communicable Diseases. SARS-CoV-2 seroprevalence in the Cape Town
383 Metropolitan Subdistricts after the peak of infections. COVID-19-Special-Public-Health-Surveillance-
384 Bulletin_Issue-5.pdf (accessed May 15, 2023).
- 385 6. Otieno NA, Azziz-Baumgartner E, Nyawanda BO, et al. SARS-CoV-2 infection among pregnant and
386 postpartum women, Kenya, 2020–2021. *Emerg Infect Dis* 2021; **27(9)**: 2497–99.
- 387 7. Abdullahi A, Oladele D, Owusu M, et al. SARS-CoV-2 antibody responses to AZD1222 vaccination in
388 West Africa. *Nat Commun* 2022; **13**: 6131.
- 389 8. Sawry S, Le Roux J, Wolter N, et al. High prevalence of SARS-CoV-2 antibodies in pregnant women
390 after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South
391 Africa. *Int J Infect Dis* 2022; **125**: 241–49.
- 392 9. Gonzalez R, Nhampossa T, Figueroa-Romero A, et al. SARS-CoV-2 seropositivity and HIV viral load
393 among Mozambican pregnant women. *J Acquir Immune Defic Syndr* 2023; **92(2)**: 115–21.
- 394 10. Assefa N, Regassa LD, Teklemariam Z, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in women
395 attending antenatal care in eastern Ethiopia: a facility-based surveillance. *BMJ Open* 2021; **11**:
396 e055834.
- 397 11. Lucinde RK, Mugo D, Bottomley C, et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care
398 clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21. *PLoS ONE* 2022;
399 **17(10)**: e0265478.
- 400 12. Duarte N, Yanes-Lane M, Arora RK, et al. Adapting serosurveys for the SARS-CoV-2 vaccine era. *Open*
401 *Forum Infect Dis* 2021; <https://doi.org/10.1093/ofid/ofab632>.
- 402 13. UNICEF. COVID-19 Market Dashboard. Dec 21, 2020. [https://www.unicef.org/supply/covid-19-](https://www.unicef.org/supply/covid-19-market-dashboard)
403 [market-dashboard](https://www.unicef.org/supply/covid-19-market-dashboard) (accessed Jun 12, 2023).
- 404 14. Lusaka Times. Zambia celebrates 770 percent COVID-19 vaccination achievement. Nov 2, 2022.
405 [https://www.lusakatimes.com/2022/11/02/zambia-celebrates-70-percent-covid-19-vaccination-](https://www.lusakatimes.com/2022/11/02/zambia-celebrates-70-percent-covid-19-vaccination-achievement/)
406 [achievement/](https://www.lusakatimes.com/2022/11/02/zambia-celebrates-70-percent-covid-19-vaccination-achievement/) (accessed Jun 12, 2023).

- 407 15. Zambia Statistics Agency. Zambia demographic and health survey 2018. Jan 2020.
408 <https://www.zamstats.gov.zm/download/5400/?tmstv=1684233605&v=5436> (accessed Sep 25,
409 2020).
- 410 16. Makasa M, Fylkesnes K, Michelo C, Kayeyi N, Chirwa B, Sandoy I. Declining syphilis trends in
411 concurrence with HIV declines among pregnant women in Zambia: Observations over 14 years of
412 national surveillance. *Sex Transm Dis* 2012; **39(3)**: 173–81.
- 413 17. Gutman JR, Mwesigwa JN, Arnett K, et al. Using antenatal care as a platform for malaria surveillance
414 data collection: study protocol. *Malar J* 2023; **22**: 99.
- 415 18. Kangale C, Musunse M, Phiri-Chibawe C, et al. Routine malaria prevalence and intervention
416 coverage estimates obtained by surveying antenatal care (ANC) attendees in Chadiza District,
417 Eastern Province, Zambia: progress and lessons learned. ASTMH 2020. LB-5073
- 418 19. Tetracore Inc. Instructions for use: Tetracore FlexImmArray SARS-CoV-2 Human IgG Antibody Test.
419 [https://tetracore.com/wp-content/uploads/2021/04/FlexImmArraySARS-CoV-](https://tetracore.com/wp-content/uploads/2021/04/FlexImmArraySARS-CoV-2IlgGkitIFU_ver05122020_web.pdf)
420 [2IlgGkitIFU_ver05122020_web.pdf](https://tetracore.com/wp-content/uploads/2021/04/FlexImmArraySARS-CoV-2IlgGkitIFU_ver05122020_web.pdf) (accessed Jan 9, 2023).
- 421 20. Tartof SY, Xie F, Yadav R, et al. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness
422 against outpatient illness during widespread circulation of SARS-CoV-2 omicron variant, US Flu VE
423 Network. *medRxiv* 2023; published online Jan 11, 2023.
424 <https://doi.org/10.1101/2023.01.10.23284397> (preprint).
- 425 21. Mitchell KF, Carlson CM, Nace D, et al. Evaluation of a multiplex bead assay against single-target
426 assays for detection of IgG antibodies to SARS-CoV-2. *Microbiol Spectr*; **10(3)**:
427 <https://doi.org/10.1128/spectrum.01054-22>.
- 428 22. Zambia Statistics Agency. 2022 census of population and housing preliminary report. Dec 2022.
429 <https://www.zamstats.gov.zm/download/5578/?tmstv=1684233605&v=9742> (accessed Feb 14,
430 2023).
- 431 23. Lubeya MK, Kabwe JC, Mukosha M, et al. Maternal COVID-19 infection and associated factors: A
432 cross-sectional study. *PLoS ONE* 2023; **18(3)**: e0281435.
- 433 24. Madhi SA, Kwatra G, Myers JE, et al. Population immunity and COVID-19 severity with Omicron
434 variant in South Africa. *N Engl J Med* 2022; **386**: 1314–26.
- 435 25. Madhi SA, Kwatra G, Myers JE, et al. Sustained low incidence of severe and fatal COVID-19 following
436 widespread infection induced immunity after the Omicron (BA.1) dominant in Gauteng, South
437 Africa: An observational study. *Viruses* 2023; **15(3)**: 597.
- 438 26. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on
439 symptomatic Omicron infections. *N Engl J Med* 2022; **387**: 21–34.
- 440 27. Awandu SS, Ochieng AO, Onyango B, et al. High seroprevalence of Immunoglobulin G (IgG) and IgM
441 antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out
442 in western Kenya. *PLoS ONE* 2022; **17(12)**: e0272751.

- 443 28. Konu YR, Conde S, Gbeasor-Komlanvi F, et al. SARS-CoV-2 antibody seroprevalence in Togo: a
444 national cross-sectional household survey, May-June, 2021. *BMC Public Health* 2022; **22**: 2294.
- 445 29. Arnaldo A, Mabunda N, Young PW, et al. Prevalence of severe acute respiratory syndrome
446 coronavirus 2 (SARS-CoV-2) antibodies in the Mozambican population: a cross-sectional serologic
447 study in 3 cities, July-August 2020. *Clin Infect Dis* 2022; **75(S2)**: S285–93.
- 448 30. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April
449 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS Med*
450 2022; **19(11)**: e1004107.
- 451 31. Yadouleton A, Sander A, Moreira-Soto A, et al. Limited specificity of serologic tests for SARS-CoV-2
452 antibody detection, Benin. *Emerg Infect Dis* 2021; **27(1)**: 233–37.
- 453 32. Chaponda D. Govt lifts wearing of masks in 22 districts. *News Diggers!* Aug 15, 2022.
454 [https://diggers.news/local/2022/08/15/govt-lifts-wearing-of-masks-in-22-](https://diggers.news/local/2022/08/15/govt-lifts-wearing-of-masks-in-22-districts/#:~:text=HEALTH%20Minister%20Sylvia%20Masebo%20has,%2C%20Chingola%2C%20Chifunabuli%20and%20Luanshya)
455 [districts/#:~:text=HEALTH%20Minister%20Sylvia%20Masebo%20has,%2C%20Chingola%2C%20Chifunabuli%20and%20Luanshya](https://diggers.news/local/2022/08/15/govt-lifts-wearing-of-masks-in-22-districts/#:~:text=HEALTH%20Minister%20Sylvia%20Masebo%20has,%2C%20Chingola%2C%20Chifunabuli%20and%20Luanshya) (accessed May 12, 2023).
- 457 33. Ripperger TJ, Urhlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable
458 surveillance of low-prevalence communities and reveal durable humoral immunity. *Immunity* 2020;
459 **53**: 925–33.
- 460 34. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based analysis of the
461 longevity of SARS-CoV-2 antibody seropositivity in the United States. *EClinicalMedicine* 2021; **36**:
462 100902.
- 463

Supplementary table 1. Participant demographics, SARS-CoV-2 exposures and risk behaviors, and ANC test results					
	Chadiza	Chipata	Chongwe	Lusaka	Total
	n=1616	n=2099	n=2441	n=2148	N=8304
	n (%)	n (%)	n (%)	n (%)	n (%)
Age, median (IQR)	22 (19-28)	25 (21-30)	24 (20-30)	26 (22-30)	25 (20-30)
15-19	438 (27.1)	369 (17.6)	518 (21.2)	210 (9.8)	1535 (18.5)
20-29	760 (47.0)	1190 (56.7)	1300 (53.3)	1297 (60.4)	4547 (54.8)
30-39	251 (15.5)	481 (22.9)	531 (21.8)	576 (26.8)	1839 (22.1)
40-49	26 (1.6)	43 (2.0)	90 (3.7)	57 (2.7)	216 (2.6)
Unknown	141 (8.7)	16 (0.8)	2 (0.1)	8 (0.4)	167 (2.0)
Education					
No education	377 (23.3)	171 (8.1)	77 (3.2)	31 (1.4)	656 (7.9)
Some primary	779 (48.2)	518 (24.7)	809 (33.1)	413 (19.2)	2519 (30.3)
Completed primary	133 (8.2)	553 (26.3)	608 (24.9)	337 (15.7)	1631 (19.6)
Some secondary	200 (12.4)	612 (29.2)	732 (30.0)	805 (37.5)	2349 (28.3)
Completed secondary or higher	123 (7.6)	240 (11.4)	215 (8.8)	559 (26.0)	1137 (13.7)
Unknown	4 (0.2)	5 (0.2)	0 (0.0)	3 (0.1)	12 (0.1)
Occupation					
Farmer	1383 (85.6)	443 (21.1)	602 (24.7)	10 (0.5)	2438 (24.9)
Daily laborer/pieceworker	8 (0.5)	78 (3.7)	325 (13.3)	64 (3.0)	475 (5.7)
Merchant/shop owner	12 (0.7)	56 (2.7)	55 (2.3)	108 (5.0)	231 (2.8)
Health worker	8 (0.5)	16 (0.8)	6 (0.2)	13 (0.6)	43 (0.5)
Government employee/civil servant	27 (1.7)	47 (2.2)	17 (0.7)	88 (4.1)	179 (2.2)
Private sector employee	6 (0.4)	31 (1.5)	25 (1.0)	145 (6.8)	207 (2.5)
Hawker/market seller	14 (0.9)	142 (6.8)	164 (6.7)	241 (11.2)	561 (6.8)
Student	89 (5.5)	95 (4.5)	79 (3.2)	111 (5.2)	374 (4.5)
Unemployed	63 (3.9)	996 (47.5)	1088 (44.6)	1195 (55.6)	3342 (40.2)
Other occupation	1 (0.1)	162 (7.7)	54 (2.2)	162 (7.5)	379 (4.6)
Unknown	5 (0.3)	33 (1.6)	26 (1.1)	11 (0.5)	75 (0.9)
Prior COVID-19					
No	1565 (96.8)	2031 (96.8)	2375 (97.3)	2054 (95.6)	8025 (96.8)
Yes	42 (2.6)	42 (2.0)	31 (1.3)	64 (3.0)	179 (2.2)
Unknown	9 (0.6)	26 (1.2)	35 (1.4)	30 (1.4)	100 (1.2)
Household COVID-19					
No	1573 (97.3)	2014 (96.0)	2276 (93.2)	1983 (92.3)	7846 (94.5)
Yes	36 (2.2)	49 (2.3)	48 (2.0)	137 (6.4)	270 (3.3)
Unknown	7 (0.4)	36 (1.7)	117 (4.8)	28 (1.3)	188 (2.3)
Close COVID-19 contact [†]					
No	1439 (89.0)	1953 (93.0)	1993 (81.6)	1862 (86.7)	7247 (87.3)
Yes	30 (1.9)	52 (2.5)	62 (2.5)	176 (8.2)	320 (3.9)


Unknown	147 (9.1)	94 (4.5)	386 (15.8)	110 (5.1)	737 (8.9)
COVID-19 vaccination [†]					
No	1089 (67.4)	1633 (77.8)	1925 (78.9)	1904 (88.6)	6551 (78.9)
Yes	511 (31.6)	452 (21.5)	486 (19.9)	236 (11.0)	1685 (20.3)
Unknown	16 (1.0)	14 (0.7)	30 (1.2)	8 (0.4)	68 (0.8)
Co-infections, positive/tested					
HIV	48/1586 (3.0)	279/2075 (13.4)	215/2362 (9.1)	164/2008 (8.2)	706/8031 (8.8)
Syphilis	6/956 (0.6)	11/538 (2.0)	7/736 (1.0)	22/1108 (2.0)	46/3338 (1.4)
Hepatitis B	0/400 (0.0)	0/91 (0.0)	0/41 (0.0)	13/441 (2.9)	13/973 (1.3)
Malaria	190/1616 (11.8)	18/512 (3.5)	6/493 (1.2)	27/464 (5.8)	241/3085 (7.8)
COVID-19 risk behaviors [§]	n=988	n=1382	n=1690	n=1334	N=5394
Mask use in public all or most of the time (self-report)	428 (43.3)	398 (28.8)	755 (44.7)	1090 (81.7)	2671 (49.5)
Proper mask use during ANC visit	574 (58.1)	429 (31.0)	873 (51.7)	783 (58.7)	2659 (49.3)
Travel outside district	41 (4.1)	47 (3.4)	93 (5.5)	100 (7.5)	281 (5.2)
Travel outside Zambia	6 (0.6)	11 (0.8)	5 (0.3)	16 (1.2)	38 (0.7)
Visit to church or mosque	544 (55.1)	993 (71.9)	1201 (71.1)	886 (66.4)	3624 (67.2)
Visit to wedding or funeral	236 (23.9)	698 (50.5)	381 (22.5)	407 (30.5)	1722 (31.9)
Visit to market or grocery store	355 (35.9)	1014 (73.4)	1136 (67.2)	1081 (81.0)	3586 (66.5)
Indoor dining	64 (6.5)	437 (31.6)	250 (14.8)	352 (26.4)	1103 (20.4)
Use of public transportation	77 (7.8)	918 (66.4)	792 (46.9)	989 (74.1)	2776 (51.5)
ANC=antenatal care, IQR=interquartile range. [†] Close contact defined as being within 2 meters of someone outside the household suspected or confirmed to have COVID-19 for greater than 15 minutes; [‡] ≥1 dose of any COVID-19 vaccine; [§] Responses restricted to February-September 2022					



465

466 Figure 1. Reported COVID-19 cases among the general population and SARS-CoV-2 seroprevalence among study
 467 participants, by district. Serologic testing was done using the Tetracore FlexImmArray SARS-CoV-2 Human IgG
 468 Antibody Test; a positive result was assigned if signal ratios ≥ 1.2 for all 3 assay targets (nucleocapsid [N], receptor-
 469 binding domain [RBD] of the spike protein, and N-RBD fusion). Seroprevalence was adjusted for assay performance
 470 (sensitivity=89.8% and specificity=100%) and error bars represent 95% confidence intervals.


471



472

473 Supplementary figure 1. Antibody response categorization based on anti-RBD IgG, anti-nucleocapsid IgG, and
474 COVID-19 vaccination status (N=8,304). The Tetracore FlexImmArray SARS-CoV-2 Human IgG Antibody Test used is
475 a multiplex bead assay with three SARS-CoV-2 targets (i.e., nucleocapsid, receptor-binding domain (RBD) of spike,
476 and fusion) to facilitate distinguishing between infection only, vaccination only, and combined vaccination and
477 infection antibody responses when considered with vaccination history. Participants who reported receiving a
478 Sinopharm or unknown vaccine were categorized as indeterminate due to the inability to distinguish between
479 vaccination only and hybrid vaccination and infection antibody responses from inactivated or attenuated virus
480 vaccines. Adapted from Duarte et al. 2021.


481



482

483 Figure 2. SARS-CoV-2 antibody response categorization of study participants by enrollment month and district. No
 484 evident antibody response was defined as testing negative for anti-RBD IgG. Infection-derived antibody response
 485 was defined as positive anti-RBD IgG AND no reported COVID-19 vaccination. Vaccination and infection-derived
 486 hybrid antibody response was defined as positive anti-RBD IgG AND positive anti-nucleocapsid IgG AND reported
 487 COVID-19 vaccination. Vaccination-derived antibody response was defined as positive anti-RBD IgG AND reported
 488 COVID-19 vaccination AND negative anti-nucleocapsid IgG. Equivocal IgG responses, unknown COVID-19
 489 vaccination status, and unknown or Sinopharm vaccine type were categorized as indeterminate.

490



491
492 Figure 3. Signal ratios for three assay targets by antibody response category. Signal ratios were calculated by
493 dividing the mean fluorescent intensity of the target by the mean fluorescent intensity of the calibrators.
494 Vaccination and infection combined produced the strongest antibody response against all three assay targets
495 compared to infection or vaccination alone. Participants whose antibody response was derived from infection only
496 had greater signal ratios for the RBD target compared to participants with vaccination-derived antibody response
497 only. ns=not significant (p-value>0.05); **p-value<0.001

Table 1. SARS-CoV-2 seropositivity by participant demographics and SARS-CoV-2 exposures and risk behaviors

	Chadiza		Chipata		Chongwe		Lusaka	
	SARS-CoV-2 Seropositive	Adjusted Odds Ratio	SARS-CoV-2 Seropositive	Adjusted Odds Ratio	SARS-CoV-2 Seropositive	Adjusted Odds Ratio	SARS-CoV-2 Seropositive	Adjusted Odds Ratio
	n (%)	aOR 95% CI	n (%)	aOR 95% CI	n (%)	aOR 95% CI	n (%)	aOR 95% CI
Total	707 (43.8)		1433 (68.3)		1565 (64.1)		1591 (74.1)	
Age								
15-19	182 (41.6)	1 (ref)	244 (66.1)	1 (ref)	330 (63.7)	1 (ref)	154 (73.3)	1 (ref)
20-29	343 (45.1)	1.23 (0.96-1.58)	808 (67.9)	1.12 (0.86-1.46)	823 (63.3)	1.00 (0.80-1.25)	947 (73.0)	0.98 (0.69-1.40)
30-39	114 (45.4)	1.12 (0.80-1.56)	338 (70.3)	1.31 (0.96-1.79)	352 (66.3)	1.21 (0.92-1.59)	443 (76.9)	1.22 (0.83-1.80)
40-49	12 (46.2)	1.43 (0.61-3.33)	36 (83.7)	2.76 (1.16-6.58)*	60 (66.7)	1.17 (0.70-1.95)	42 (73.7)	0.98 (0.48-2.00)
Education								
No education	156 (41.4)	0.91 (0.70-1.18)	108 (63.2)	0.86 (0.59-1.26)	44 (57.1)	1.17 (0.70-1.95)	16 (51.6)	0.44 (0.19-1.00)
Some primary	337 (43.3)	1 (ref)	329 (63.5)	1 (ref)	485 (60.0)	1 (ref)	296 (71.7)	1 (ref)
Completed primary	49 (36.8)	0.96 (0.64-1.43)	390 (70.5)	1.08 (0.82-1.41)	405 (66.6)	1.12 (0.89-1.42)	255 (75.7)	0.91 (0.64-1.30)
Some secondary	95 (47.5)	1.23 (0.88-1.70)	440 (71.9)	1.25 (0.96-1.63)	485 (66.3)	1.34 (1.07-1.67)	602 (74.8)	0.94 (0.70-1.25)
Completed secondary or higher	68 (55.3)	1.76 (1.17-2.64)*	161 (67.1)	1.14 (0.81-1.61)	146 (67.9)	1.64 (1.16-2.31)*	420 (75.1)	0.96 (0.71-1.31)
Occupation								
Farmer	596 (43.1)	0.63 (0.37-1.10)	274 (61.9)	0.66 (0.51-0.85)*	349 (58.0)	0.70 (0.56-0.87)*	9 (90.0)	2.55 (0.30-21.85)
Daily labourer/pieceworker	4 (50.0)	1.20 (0.25-5.81)	49 (62.8)	0.76 (0.46-1.26)	205 (63.1)	0.88 (0.67-1.16)	55 (85.9)	1.93 (0.90-4.15)
Merchant/shop owner	3 (25.0)	0.25 (0.06-1.08)	30 (53.6)	0.55 (0.31-0.98)*	33 (60.0)	1.08 (0.6-1.95)	83 (76.9)	1.94 (1.19-3.18)*
Health worker	4 (50.0)	1.11 (0.24-5.10)	8 (50.0)	0.50 (0.17-1.42)	5 (83.3)	4.70 (0.48-45.97)	10 (76.9)	1.60 (0.40-6.40)
Government/civil servant	13 (48.1)	0.83 (0.32-2.19)	35 (74.5)	1.16 (0.58-2.33)	15 (88.2)	5.02 (1.07-23.47)*	61 (69.3)	0.91 (0.55-1.52)
Private sector employee	3 (50.0)	0.66 (0.11-3.95)	21 (67.7)	0.91 (0.41-2.02)	20 (80.0)	3.38 (1.19-9.58)*	107 (73.8)	1.11 (0.73-1.70)
Hawker/market seller	6 (42.9)	1.05 (0.30-3.67)	102 (71.8)	1.00 (0.67-1.51)	121 (73.8)	1.56 (1.05-2.34)*	181 (75.1)	1.20 (0.86-1.69)
Student	42 (47.2)	0.61 (0.30-1.23)	70 (73.7)	1.16 (0.70-1.91)	54 (68.4)	1.15 (0.69-1.94)	88 (79.3)	0.94 (0.56-1.58)
Unemployed	34 (54.0)	1 (ref)	719 (72.2)	1 (ref)	712 (65.4)	1 (ref)	859 (71.9)	1 (ref)
Other occupation	0 (0.0)	-- --	102 (63.0)	0.76 (0.53-1.10)	37 (68.5)	1.24 (0.66-2.33)	129 (79.6)	1.34 (0.87-2.06)
Prior COVID-19								
No	678 (43.3)	1 (ref)	1389 (68.4)	1 (ref)	1525 (64.2)	1 (ref)	1518 (73.9)	1 (ref)
Yes	28 (66.7)	3.06 (1.55-6.07)*	28 (66.7)	0.95 (0.48-1.89)	22 (71.0)	1.68 (0.72-2.95)	52 (81.2)	1.25 (0.64-2.45)
Household COVID-19								
No	684 (43.5)	1 (ref)	1379 (68.5)	1 (ref)	1451 (63.8)	1 (ref)	1458 (73.5)	1 (ref)
Yes	17 (47.2)	1.20 (0.60-2.38)	31 (63.3)	0.95 (0.51-1.77)	36 (75.0)	1.45 (0.71-2.95)	112 (81.8)	1.19 (0.75-1.91)
Close COVID-19 contact [†]								
No	629 (43.7)	1 (ref)	1348 (69.0)	1 (ref)	1277 (64.1)	1 (ref)	1365 (73.3)	1 (ref)
Yes	11 (36.7)	0.93 (0.42-2.05)	32 (61.5)	0.80 (0.44-1.46)	41 (66.1)	0.95 (0.53-1.67)	140 (79.5)	1.10 (0.73-1.66)
COVID-19 vaccination [†]								
No	396 (36.4)	1 (ref)	1057 (64.7)	1 (ref)	1164 (60.5)	1 (ref)	1379 (72.4)	1 (ref)
Yes	299 (58.5)	1.76 (1.40-2.21)*	363 (80.3)	1.48 (1.13-1.93)*	381 (78.4)	1.40 (1.09-1.80)*	208 (88.1)	1.97 (1.29-3.02)*

HIV status								
Negative	767 (44.0)	1 (ref)	1212 (67.5)	1 (ref)	1404 (65.4)	1 (ref)	1388 (75.3)	1 (ref)
Positive	16 (33.3)	0.83 (0.43-1.59)	203 (72.8)	1.42 (1.05-1.90)*	113 (52.6)	0.77 (0.57-1.05)	104 (63.4)	0.87 (0.60-1.26)

aOR = adjusted odds ratio (adjusted for enrollment month); CI = confidence interval. †Close contact defined as being within 2 meters of someone outside the household suspected or confirmed to have COVID-19 for greater than 15 minutes; ‡≥1 dose of any COVID-19 vaccine. *p-value<0.05

498

499

500

Table 2. SARS-CoV-2 seroprevalence among vaccinated participants (n=1685)						
	SARS-CoV-2 Seropositive		SARS-CoV-2 Seronegative		Adjusted Odds Ratio	
	n	(%)	n	(%)	aOR	(95% CI)
Vaccination status						
Partially vaccinated	123	(70.3)	52	(29.7)	0.74	(0.51-1.07)
Full primary series	1106	(74.9)	370	(25.1)	1	(ref)
Vaccine type						
Oxford/AstraZeneca (ChAdOx1-S)	150	(64.9)	81	(35.1)	1	(ref)
J&J/Janssen (Ad.26.COV2.S)	965	(75.7)	309	(24.3)	1.28	(0.92-1.79)
Pfizer-BioNTech (BNT162b2)	50	(75.8)	16	(24.2)	0.71	(0.36-1.39)
Sinopharm	32	(72.7)	12	(27.3)	0.79	(0.37-1.69)
Mixed	21	(91.3)	2	(8.7)	2.82	(0.60-13.26)
Other	7	(100.0)	0	(0.0)	--	--
Months between first dose and enrollment						
<1 month	290	(69.5)	127	(30.5)	1	(ref)
1-5 months	669	(75.8)	214	(24.2)	1.58	(1.19-2.10)*
≥6 months	223	(81.4)	51	(18.6)	1.48	(0.99-2.22)
aOR=adjusted odds ratio (adjusted for district and enrollment month); CI=confidence interval. *p<0.05						

501

502

503

Table 3. Characteristics participants reporting prior COVID-19 by SARS-CoV-2 serostatus (n=179)					
	SARS-CoV-2 Seropositive		SARS-CoV-2 Seronegative		Adjusted Odds Ratio
	n	(%)	n	(%)	aOR (95% CI)
Hospitalized due to COVID-19					
No	100	(78.7)	39	(79.6)	1 (ref)
Yes	27	(21.3)	10	(20.4)	0.63 (0.24-1.66)
Months between diagnosis and enrollment					
<6 months	20	(18.3)	13	(31.0)	1 (ref)
6-11 months	41	(37.6)	12	(28.6)	1.02 (0.37-2.79)
≥12 months	48	(44.0)	17	(40.5)	0.41 (0.11-1.51)
COVID-19 vaccination[†]					
No	54	(41.9)	37	(75.5)	1 (ref)
Yes	75	(58.1)	12	(24.5)	4.11 (1.80-9.41)*
aOR=adjusted odds ratio (adjusted for district and enrollment month); CI=confidence interval. [†] Received ≥1 doses of any COVID-19 vaccine. *p<0.05					

504


505

506

Table 4. Estimated populations exposed to SARS-CoV-2 and ratios of peak seroprevalence to cumulative incidence during last survey month				
	Chadiza	Chipata	Chongwe	Lusaka
Peak SARS-CoV-2 seroprevalence [†]	77.2%	97.3%	96.8%	100.0%
2022 census population	111,069	327,059	313,389	2,204,059
Reported COVID-19 cases	2,761	8,096	3,303	75,990
Cumulative incidence [‡]	2.5%	2.5%	1.1%	3.4%
Estimated population with evidence of SARS-CoV-2 exposure [§]	85,745	318,228	303,361	2,204,059
Ratio of seroprevalence to cumulative incidence	31:1	39:1	92:1	29:1
[†] Peak SARS-CoV-2 seroprevalence for Chadiza District was April 2022; for Chipata District, peak was August 2022; for Chongwe district, peak was August 2022; for Lusaka District, peak was September 2022. [‡] Calculated as reported cases divided by population projection. [§] Calculated as seroprevalence multiplied by population projection. 2022 census data were obtained from the Zambia Statistics Agency and reported COVID-19 cases were obtained from the Zambia National Public Health Institute.				

507

508



medRxiv preprint doi: <https://doi.org/10.1101/2024.01.02.24300729>; this version posted January 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure



Figure 2




Figure 3

